Abstract: In this article, a synthesis procedure is proposed to achieve desired radiation pattern in standing-wave structure. To obtain the desired pattern, transmission line model is used, also. In ...

It was a banner year for horror, which not only dominated commercial markets but also broke through the awards barrier. The ...

A surge of 147% in a single session is an unusual occurrence in biotech — and nearly unprecedented for a company that has spent years trading discreetly under the radar. However, that is precisely ...

Compass announced a $10B all-stock acquisition of Anywhere, adding over 340,000 agents. The deal is expected to close in late 2026 but may face antitrust scrutiny and possible asset divestitures in ...

Wave Life Sciences' shares fell sharply after the clinical-stage biotechnology company priced an upsized $350 million equity raising. The shares were down 10% at $19.09 in early trading Wednesday, ...

It wasn't hard to be optimistic about the biotech's future, given its excellent news from the lab on Monday. Prognosticators fell over themselves publishing bullish new takes on the company the ...

It wasn't hard to be optimistic about the biotech's future, given its excellent news from the lab on Monday. Prognosticators fell over themselves publishing bullish new takes on the company the ...

Wave Life Sciences shares jumped in premarket trading Monday after it said it received encouraging preliminary trial data for its investigational weight loss drug WVE-007. Shares advanced nearly 78% ...

The biotech's investigational weight loss drug did very well in a clinical trial. This is a white-hot segment of the pharmaceutical market, so it's little wonder investors subsequently pounced on the ...

Wave Life Sciences Ltd. (NASDAQ: WVE) on Monday shared interim data from the lowest therapeutic cohort of the ongoing first-in-human INLIGHT trial evaluating WVE-007, an investigational INHBE ...

Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% ...

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform ...